Brief: Inovio Announces Positive Preliminary Results From Second Cohort Of Phase 1/2 Trial With Ino-3107 For The Treatment Of Recurrent Respiratory Papillomatosis

Inovio Pharmaceuticals

16/02/2023 13:12

Feb 16 (Reuters) - Inovio Pharmaceuticals Inc  INO.O :
    * INOVIO ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM SECOND
COHORT
OF PHASE 1/2 TRIAL WITH INO-3107 FOR THE TREATMENT OF RECURRENT
RESPIRATORY PAPILLOMATOSIS
    * INOVIO PHARMACEUTICALS - INO-3107 WAS WELL-TOLERATED &
IMMUNOGENIC, WITH EFFICACY AND SAFETY RESULTS FOR SECOND COHORT
CONSISTENT WITH FIRST COHORT
    * INOVIO PHARMACEUTICALS INC - TREATMENT WITH INO-3107
ACHIEVED
STATISTICAL SIGNIFICANCE BASED ON CLINICAL ENDPOINT
    * INOVIO PHARMACEUTICALS INC - TREATMENT-EMERGENT ADVERSE
EVENTS
OBSERVED IN TRIAL OF INO-3107 WERE GENERALLY LOW-GRADE

Source text for Eikon:  ID:nPn4Tlf25a 
Further company coverage:  INO.O 
 ((reuters.briefs@thomsonreuters.com;))